Skip to main content
. 2010 Oct 16;21(2):122–133. doi: 10.1007/s10165-010-0366-7

Table 3.

Cause of tocilizumab discontinuation

Cause of discontinuation Number of cases/events
Lack of efficacy 12 cases (5.2%)
Adverse events 26 cases (11.4%)
  Pneumonia 6
  Heart failure 3
  Worsening comorbidity 3
  Liver damage 2
  Interstitial pneumonia 2
  Skin ulcer 2
  Cerebellar hemorrhage 2
  Anaphylaxis 1
  Chest pain 1
  Myocardial infarction 1
  Leukopenia 1
  Breast cancer 1
  Phlegmon 1
Miscellaneous 9 cases (3.9%)
  Unknown 4
  Moving 3
  Patient’s will 2
Total 47 cases (20.5%)